When do the METHADOSE patents expire, and when will METHADOSE go generic?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Specgx Llc	METHADOSE	methadone hydrochloride	CONCENTRATE;ORAL	017116-002	Approved Prior to Jan 1, 1982	AA	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Specgx Llc	METHADOSE	methadone hydrochloride	TABLET;ORAL	040050-002	Apr 15, 1993		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Specgx Llc	METHADOSE	methadone hydrochloride	TABLET, FOR SUSPENSION;ORAL	074184-001	Apr 29, 1993	AA	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Specgx Llc	METHADOSE	methadone hydrochloride	TABLET;ORAL	040050-001	Apr 15, 1993		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 20, 2026

METHADOSE (methadone hydrochloride) Investment Scenario and Patent/Exclusivity Fundamentals

Executive summary: METHADOSE is an FDA-approved methadone oral solution used for opioid use disorder (OUD) maintenance and for pain in specific contexts. The investment thesis is driven by (1) entrenched demand linked to OUD treatment capacity, (2) a mature, largely generic market structure, (3) regulatory continuity risk (controlled-substance handling and REMS-style operational constraints), and (4) limited upside from new entrants except via route/delivery differentiation, authorized generics, or defense around any remaining Orange Book-protected formulations, method-of-use, or manufacturing-process patents.

What is METHADOSE, who makes it, and what revenue exposure matters for investors?

Featured snippet answer: METHADOSE is methadone hydrochloride in an oral dosage form marketed for OUD maintenance therapy and, in some labeling contexts, pain. Revenue exposure depends primarily on OUD treatment volumes, formulary adoption at specialty and integrated health systems, payer reimbursement, and substitution dynamics versus methadone equivalents (tablets, other oral solutions, and competing OUD therapies).

Key product characteristics

Active ingredient: Methadone hydrochloride
Dosage form: Oral solution (liquid)
Therapeutic area: Opioid use disorder (maintenance) and opioid analgesia contexts (label dependent on indication wording)

Commercial drivers investors track

OUD program capacity and patient retention: Methadone’s chronic-treatment profile links sales to dosing continuity and program stability.
Formulary access and distribution channel penetration: Oral solution often competes on clinician preference, dosing flexibility, and procurement economics.
Controlled-substance operational throughput: Ordering, storage, dispensing, and diversion-control protocols can constrain uptake at new sites.
Competitive displacement: Other OUD standards of care include buprenorphine (including long-acting options) and naltrexone products, which shift mix at certain prescribers.

What patents protect METHADOSE in the US, and how many are still likely to matter?

Featured snippet answer: For methadone products generally, the patent landscape is typically dominated by early-era drug substance and baseline formulation disclosures, with most meaningful exclusivities having expired. The practical investor question is whether any Orange Book-listed patents still cover specific METHADOSE formulation, method-of-manufacture, or method-of-use.

Investment implication: If METHADOSE’s Orange Book estate is thin or already expired, the drug behaves like a mature generic with limited pricing power. Upside depends on logistics, contract manufacturing leverage, and competitive differentiation rather than exclusivity.

Patent categories that typically appear on Orange Book listings for oral methadone products

Formulation patents: stabilized composition, concentration-specific solution design, viscosity/palatability excipients, or stability/shelf-life claims.
Manufacturing/process patents: purification, solvent removal, granulation-free handling, or control of impurities for methadone hydrochloride solution.
Method-of-use patents: OUD titration schedules, dosing algorithms, or patient stratification claims (less common for mature opioids but possible).
Packaging/administration patents: unit-dose or dispensing device claims tied to controlled-substance handling.

How to underwrite “still meaningful” patent coverage

Investors should treat “still meaningful” as any patent with:

Unexpired coverage dates that map to the currently marketed METHADOSE dosage form and labeling
Non-overlapping claims that block direct label-driven AB substitution of generic equivalents
Pending litigation that sustains a stay against FDA approval for a generic or 505(b)(2) applicant

When does METHADOSE lose exclusivity in the US, and does it have any meaningful 180-day generic exclusivity window?

Featured snippet answer: For methadone hydrochloride oral solutions, generic entry is usually governed by:

expiration of any remaining Orange Book patents tied to the marketed product
any relevant exclusivity periods from first-filing Paragraph IV (if they exist for the current reference product and dosage form)

Investment implication: Absent active Orange Book blocking patents, the product profile is less about exclusivity windows and more about generic substitution speed and supply continuity.

Exclusivity frameworks investors model

Patent expiration vs. FDA exclusivity: Patent expiry can be the gate, but FDA exclusivity (if any) can create a second timing step.
Switching costs: Even when legal barriers fall, contracts and clinical protocols can delay substitution.

Business use: timeline-based scenario modeling

Base case: continued stable demand with competitive price compression from generics
Downside: accelerated substitution after any legal or supply inflection
Upside: temporary holds if any remaining patents or labeling exclusivity affect generic approvals

What is the Orange Book status of METHADOSE, and what does it imply for generic entry risk?

Featured snippet answer: The Orange Book status determines whether generic manufacturers face a patent litigation pathway (Paragraph IV) or are able to rely on expiration-based freedom-to-market.

Investor read-through:

If Orange Book patents are listed and unexpired: generic applicants typically file Paragraph IV certifications; litigation and potential 30-month stays can delay approvals.
If Orange Book patents are absent or expired: approvals can proceed more quickly, pushing METHADOSE toward a low-margin generic-like commodity.

Key Orange Book decision points

Do patents cover the specific dosage strength and dosage form?
Are method-of-use claims present that would require label carve-outs for generics?
Do any formulation/process patents exist that are hard to design around?

Which companies are challenging METHADOSE, and how often do Paragraph IV filings show up in this category?

Featured snippet answer: For mature methadone products, competitive entry typically occurs via:

ANDAs to generic oral solutions
505(b)(2) routes for reformulated or different-but-comparable presentation products
occasional Paragraph IV filings where any remaining Orange Book patents still exist

Investment implication: Investor value usually comes from understanding whether the market is:

stable with multiple authorized suppliers, or
experiencing a fresh wave of approvals that triggers a price reset

What matters in litigation monitoring

Filing year and certification type (Paragraph IV vs. other)
Court outcome timing relative to FDA application review cycles
Settlement terms that can include launch date commitments or “carve-out” strategies

What patent litigation affects METHADOSE, and how do settlement terms change launch timing?

Featured snippet answer: Patent litigation and settlement agreements can shift launch timing by imposing stay periods, delayed approval, or side agreements on distribution and labeling.

Investment implication: For mature products, litigation events rarely create long duration of exclusivity, but they can:

delay entry of a specific generic entrant
preserve pricing for a narrower window
trigger supply constraints if winners of litigation control distribution

Settlement term types investors should flag

Agreed launch dates for generic entry
Mutual non-impairment language around certain labeling claims
Design-around acceptance for certain strengths or excipient profiles
Dismissal with prejudice after a date-based outcome

How does METHADOSE compare with other methadone formulations and OUD competitors for investment durability?

Featured snippet answer: METHADOSE faces two substitution vectors:

other methadone presentations (tablets, other oral solutions)
other OUD standards-of-care (buprenorphine products, including long-acting; naltrexone for select patients)

Competitive substitution map

Within methadone: product switching depends on pharmacy procurement contracts, clinician familiarity, and dose titration practicalities.
Across OUD classes: payer and guideline-driven mix shifts can reduce methadone’s share at the margin, especially where access to office-based buprenorphine is easier.

Investor underwriting focus

Market share stability in OUD maintenance populations
Demand elasticity to price changes
Contract retention with large dispensing networks

What is the FDA status of METHADOSE, and what regulatory risks could impact supply or approvals?

Featured snippet answer: METHADOSE is an FDA-approved drug product with ongoing post-approval compliance requirements. For methadone solutions, key risk areas include controlled-substance distribution compliance, manufacturing quality (CGMP), and potential labeling/REMS-like operational requirements tied to opioid risk management frameworks.

Regulatory risk categories

CGMP and quality events: could disrupt supply and shift share temporarily to competitors.
Label and risk management updates: operational changes can affect adoption.
Controlled-substance enforcement actions: diversion-related events can prompt additional scrutiny.

Manufacturing/IP operational barriers

Tight impurity controls for methadone
Stability and container-closure system requirements for oral solutions
Specialty logistics for controlled-substance distribution

What formulation, method-of-use, or manufacturing patents could still block generic substitution?

Featured snippet answer: The highest remaining risk typically sits in Orange Book-listed patents that specifically claim:

a particular methadone solution composition (concentration-specific excipients and stability profile)
a manufacturing method with enforceable process steps
a method-of-use tied to dosing/titration or specific OUD treatment protocols

Investment implication: If METHADOSE’s remaining patents are formulation/process-only and easy to design around, competitive threats accelerate. If patents are tightly tied to stability and shelf-life, design-around can be slower and riskier, supporting pricing for longer.

Generic launch scenarios for METHADOSE: what timelines and price pressure should investors model?

Featured snippet answer: In a mature methadone oral solution market, the most common outcome after legal barriers fall is swift price erosion driven by multiple generic suppliers, with temporary pockets of stability tied to:

contract lead times
pharmacy conversion cycles
supply and quality approvals for new entrants

Scenario framework

Base case (moderate competition): stable volume, controlled price compression, margin erosion offset by volume stability and contract renewals.
Downside (aggressive genericization): rapid substitution by wholesalers and pharmacy chains, pricing reset, margin compression.
Upside (limited entry or supply constraints): delayed launches due to manufacturing qualification, quality issues, or litigation-driven timing.

How strong is the patent estate for METHADOSE compared with other methadone products?

Featured snippet answer: For methadone products generally, patent estate strength is typically weak versus newer brand assets, because methadone is an established molecule with long history and broad generic availability. The investor question is not “is methadone patent-protected,” but “are there any still-relevant Orange Book patents for the specific METHADOSE oral solution and label?”

Relative strength assessment logic

Count unexpired Orange Book patents mapped to the marketed strength/dosage form
Check whether patents cover formulation/process rather than broad method-of-use
Evaluate whether active litigation or injunction risk exists (rare in mature commodity opioids, but possible if a later-life reformulation created an actionable estate)

Investment conclusion: what is the bull vs bear case for METHADOSE?

Bull case

Sustained OUD maintenance demand supports volume
Any remaining formulation/process patents slow full substitution
Supply continuity supports contract retention
Operational scale in controlled-substance distribution helps defend margin

Bear case

Orange Book protection is either absent or expired, enabling faster generic entry
Price compression accelerates with new ANDA approvals
OUD mix shifts toward alternative therapies at certain sites
Quality/manufacturing disruptions increase volatility and market share leakage

Key Takeaways

METHADOSE’s investment profile is driven by OUD treatment demand and substitution dynamics more than by long-lived patent exclusivity.
The decisive diligence item is Orange Book coverage for the specific methadone oral solution: if it is minimal or expired, generic entry risk is high and exclusivity timing is less relevant.
Near-term upside is most plausibly sourced from contracting, supply chain execution, and potential temporary holds from any remaining patent barriers.
Downside centers on accelerated generic substitution, price erosion, and any manufacturing quality or controlled-substance operational disruptions.

FAQs

1) How fast do generics typically substitute for methadone oral solutions after patent barriers expire?
Substitution speed usually tracks pharmacy contract cycles, wholesaler formulary updates, and clinician titration inertia.

2) What types of patents are most commonly asserted for older opioid oral solutions?
Formulation stability/process and packaging-related claims are most plausible where any later-life patenting exists.

3) Does OUD payer mix shifting toward buprenorphine affect METHADOSE demand?
Yes at the margin, especially in settings where buprenorphine access is easier, but methadone remains a core maintenance option for many programs.

4) What operational risks can move METHADOSE supply and price independently of patent status?
CGMP quality events and controlled-substance logistics constraints can rapidly reshape local availability and pricing.

5) Are settlement agreements in methadone cases usually about launch dates or label carve-outs?
Typically about launch timing and approval sequencing; label carve-outs arise when method-of-use claims are asserted.

References (APA)

No sources were provided in the prompt, and no verifiable bibliographic citations can be produced without external document access.

METHADOSE Drug Patent Profile

When do Methadose patents expire, and what generic alternatives are available?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Methadose

AI Deep Research

Questions you can ask:

Summary for METHADOSE

US Patents and Regulatory Information for METHADOSE